Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antineoplastons + Radiation in DIPG
NCT02887040Phase 3Not yet recruiting
- Sponsor
- Burzynski Research Institute
- Start
- Oct 2025
- Primary completion
- Jun 2026
- Modality
- Peptides, Small Molecules
01
Overview
A Phase 3 trial of antineoplaston A10, antineoplaston AS2-1 in diffuse intrinsic pontine glioma (DIPG), sponsored by Burzynski Research Institute. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
antineoplaston A10antineoplaston AS2-1
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT02887040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02887040.